Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
COVID-19
Type of publications
Guidelines (1)
NITAG documentation (354)
SAGE documentation (33)
Scientific publications (4)
Systematic reviews (SYSVAC) (1089)
Regions
Africa (57)
Americas (187)
Eastern Mediterranean (10)
Europe (155)
South-East Asia (10)
Western Pacific (36)
Diseases
COVID-19 (1481)
Chikungunya (9)
Cholera (33)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (266)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
Methodological quality (AMSTAR 2)
High (12)
Moderate (7)
Low (111)
Critically low (685)
Not applicable (274)
1481 results found
2021
∙
JCVI
JCVI issues updated advice on COVID-19 vaccination of children aged 12 to 15 - 3 September, 2021
2021
∙
JCVI
JCVI issues updated advice on COVID-19 vaccination of young people aged 16 to 17 - 4 August 2021
2021
∙
JCVI
JCVI statement on COVID-19 vaccination of children and young people aged 12 to 17 years: 15 July 2021
2021
∙
JCVI, Public Health England
JCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021
2021
∙
ATAGI
Joint statement on COVID-19 AstraZeneca vaccine advice from ATAGI - 20 May, 2021
2021
∙
ACIP
Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Janssen COVID-19 Vaccine
2021
Mandatory vaccination of healthcare personnel
2021
∙
Haute Autorité de Santé, Commission Technique des Vaccinations
Modification of the vaccine schedule against SARS-CoV-2 in the new epidemic context
2021
∙
NACI
NACI has updated its recommendations on the use of COVID-19 vaccines to include advice on the use of the Janssen COVID-19 vaccine - May 3, 2021
2021
∙
NACI
NACI issues updated recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age - 27 August, 2021
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register
